Acneiform eruption from epidermal growth factor receptor inhibitors;Erupción acneiforme por inhibidores del receptor de crecimiento epidérmico

Actas Dermo-Sifiliograficas

Volumn 96, Issue 7, 2005, Pages 450-454

  Martínez De Lagrán, Zuriñe ^a   Ratón, Juan A ^a   Lasa, Olatz ^a   Acebo, Elvira ^a   Díaz Pérez, José L ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

Acneiform eruption; Cutaneous toxicity; Epidermal growth factor receptor inhibitors

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ACNE; ADULT; AGED; ARTICLE; CANCER RESEARCH; CASE REPORT; FEMALE; HOMEOSTASIS; HUMAN; MALE; RASH; SKIN TOXICITY;

EID: 27244445645     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-7310(05)73110-0     Document Type: Article

References (13)

1. Ciardiello F, De Vita F, Orditura M, Tortora G. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol. 16:130-5.
2. Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa®), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147: 598-601.
3. Álvarez-Ruiz SB, Dauden E. Efectos dermatológicos de gefitinib (iressa) un nuevo agente contra el cáncer. Dermatol Pract. 2004;12:10-3.
4. Lee MW, Seo CW, Kim SW, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa® (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol. 2004;84:23-6.
5. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169-76.
6. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol. 2004;151: 238-41.
7. Zandwijk N. Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. Br J Cancer. 2003; 89:89-814.
8. Isarría MJ, Alonso I, Segurado A, Ortiz J, Vanaclocha F. Reacción cutánea secundaria a tratamiento con Iressa (ZD1839). Actas Dermosifiliogr. 2004;95:459-61.
9. Fernández-Galar M, España A, López-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol. 2004; 29:138-40.
10. Pascual JC, Bañuls J, Belinchon I, Blanes M, Massuti B. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol. 2004;151:1111-2.
11. Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KJ. Epidermal growth factor receptor inhibition induces trichomegalia. Acta Oncol. 2003;42:345-6.
12. Yang TS, Chen KJ, Yin MC, Wang RC, Lin YC. Paronychia and skin hiperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22: 4646-8.
13. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110-24.